<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15393">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02906488</url>
  </required_header>
  <id_info>
    <org_study_id>P15-720</org_study_id>
    <nct_id>NCT02906488</nct_id>
  </id_info>
  <brief_title>Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease</brief_title>
  <official_title>Special Drug Use Results Survey of Safety and Efficacy of Long-term (104 Weeks) Use of Duodopa Enteral Solution in Patients With Parkinson's Disease in Actual Usage Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of long-term use of Duodopa
      in patients with Parkinson's disease in actual usage
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in &quot;Off&quot; Periods From Start of Treatment to Week 104</measure>
    <time_frame>104 weeks</time_frame>
    <description>&quot;Off&quot; periods describe those times when medication is not working well and a person has greater difficulty with movement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-dependent Change in &quot;Off&quot; Time and &quot;On&quot; Time Accompanied By Dyskinesia Interfering with Daily Activities</measure>
    <time_frame>104 Weeks</time_frame>
    <description>&quot;Off&quot; periods describe those times when medication is not working well and a person has greater difficulty with movement, and &quot;On&quot; periods describe when medication is working well and symptoms are controlled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-dependent Change in Unified Parkinson's Disease Rating Scale (UPDRS)</measure>
    <time_frame>104 Weeks</time_frame>
    <description>Motor evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-dependent Change in Parkinson's Disease Questionnaire - 8 Items (PDQ-8)</measure>
    <time_frame>104 weeks</time_frame>
    <description>The PDQ-8 is a quality of life questionnaire for PD patient. This short-form version derived from the PDQ-39 includes 1 question from each of the domains on the PDQ-39 (mobility, ADLs, emotional well-being, stigma, social support, cognitions, communication, and bodily discomfort).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-dependent Change in Parkinson's Disease Quality of Life Questionnaire - Carers (PDQ-Carer)</measure>
    <time_frame>104 weeks</time_frame>
    <description>The PDQ-Carer is a 29 item measure of health related quality of life for use with carers of people with Parkinson's disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&quot;Off&quot; Period and &quot;On&quot; Period Accompanied by Dyskinesia Interfering with Daily Activities by Patient Characteristic Factor</measure>
    <time_frame>104 weeks</time_frame>
    <description>&quot;Off&quot; periods describe those times when medication is not working well and a person has greater difficulty with movement, and &quot;On&quot; periods describe when medication is working well and symptoms are controlled.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Patients with Parkinson's Disease</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Parkinson's disease using Duodopa for the purpose of improving circadian
        change (wearing-off phenomenon) of symptoms of Parkinson's disease in which sufficient
        effect cannot be obtained with existing drug therapy including levodopa-containing drugs.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Patients with Parkinson's disease using Duodopa for the purpose of improving circadian
        change (wearing-off phenomenon) of symptoms of Parkinson's disease in which sufficient
        effect cannot be obtained with existing drug therapy including levodopa-containing drugs.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osamu Mikami, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbvie GK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbbVie_Japan PMOS_desk</last_name>
    <phone>+81-3-4577-1125</phone>
    <email>AbbVie_JPN_info_clingov@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tomoya Umezaki</last_name>
    <email>tomoya.umezaki@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155744</name>
      <address>
        <city>Asahikawa-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 155744, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 160830</name>
      <address>
        <city>Kashihara</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 160830</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 160818</name>
      <address>
        <city>Kitakyusyu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 160818, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 160824</name>
      <address>
        <city>Kodaira</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 160824, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 160825</name>
      <address>
        <city>Sagamihara</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 160825, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 160831</name>
      <address>
        <city>Sendai</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 160831, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 160823</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 160823, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 160817</name>
      <address>
        <city>Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 160817, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
    <description>Related Info.</description>
  </link>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 31, 2017</lastchanged_date>
  <firstreceived_date>September 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
